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Abstract Gastric cancer remains a prevalent disease world-
wide with a poor prognosis.Helicobacter pylori plays a major
role in gastric carcinogenesis. H. pylori colonization leads to
chronic gastritis, which predisposes to atrophic gastritis, intes-
tinal metaplasia, dysplasia, and eventually gastric cancer.
Screening, treatment, and prevention ofH. pylori colonization
can reduce the incidence of gastric cancer. Other interventions
that may yield a similar effect, although of smaller magnitude,
include promotion of a healthy lifestyle including dietary mea-
sures, non-smoking, low alcohol intake, and sufficient physi-
cal activity. This chapter reviews interventions that can lead to
a decline in gastric cancer incidence in high and low incidence
countries.
Keywords Gastric cancer . Epidemiology . Prevention .
Helicobacter pylori . Diet . Screening
Introduction
Despite its declining incidence, gastric cancer is still the fourth
most commonmalignancy and remains the third leading cause
of cancer-related death, following lung and liver cancer [1].
Despite medical progress, less than 30 % of subjects diag-
nosed with gastric cancer survive for more than 5 years. In
2012, almost a million gastric cancer cases were diagnosed
and over 700,000 persons died from the disease [2]. The ma-
jority of cases occurred in Asia and Eastern Europe; however,
gastric cancer is also common in certain areas of Middle and
South America (Fig. 1). There are marked differences within
many geographic areas, with considerably higher gastric can-
cer incidences among indigenous populations [3].
Most cases of gastric cancer are intestinal-type adenocarci-
nomas and the majority is localized in the antrum and body of
the stomach. Non-cardia intestinal adenocarcinomas are
thought to develop via a specific pathway first described by
Correa in 1975 [4]. This pathway starts with chronic active
gastritis leading to gland loss and development of atrophic
gastritis, intestinal metaplasia, and dysplasia to eventually re-
sult in gastric adenocarcinoma.
The predominant risk factor for gastric cancer is
Helicobacter pylori gastritis. The decrease in prevalence
of H. pylori significantly contributed to the declining in-
cidence of gastric cancer in many parts of the world.
Nevertheless, the annual numbers of patients diagnosed
with and dying from gastric cancer remained to increase
till now, in particular due to the growing population in
areas with high H. pylori prevalence [5]. Although the
absolute numbers of gastric cancer are decreasing in
Western countries, some studies suggest different patterns
in various age groups, with in particular a significant in-
crease in premalignant lesions and gastric cancer among
younger patients [6, 7].
Colonization with H. pylori is not the sole determi-
nant for the development of gastric cancer. Risk modu-
lators are in particular related to lifestyle. The recogni-
tion of these risk modulators determines the options for
prevention and intervention to decrease the incidence of
gastric cancer.
This article is part of the Topical Collection on GI Oncology
* Caroline M. den Hoed
c.denhoed@erasmusmc.nl
1 Department of Gastroenterology and Hepatology, Erasmus MC
University Medical Center, Rotterdam, The Netherlands
Curr Gastroenterol Rep (2016) 18: 34
DOI 10.1007/s11894-016-0506-0
Helicobacter pylori
H. pylori gastritis primarily determines the risk for gastric
cancer. Ubiquitous eradication of H. pylori by means of
population screening and intervention programs would
consequently lead to a major reduction in gastric cancer
incidence worldwide. Large population-based studies in
China and Taiwan, and case-control studies in Japan have
shown a clear risk reduction by means of H. pylori
eradication.
In 1995, the Shandong Intervention trial was initiated in
Linqu, China. The goal of this intervention trial was to study
the impact of screening and treatment for H. pylori on the
incidence of precancerous gastric lesions and gastric cancer
[8]. In total, 3365 subjects were randomly assigned to receive
H. pylori eradication treatment or placebo. After 15 years of
follow-up, H. pylori eradication was shown to significantly
reduce gastric cancer incidence with 39 % compared to place-
bo treatment. Adjusting for other risk factors such as age, sex,
alcohol, and smoking did not change the outcomes (OR 0.61
95 % CI 0.38–0.96) [9•]. Another study with approximately
the same design was performed in Southern China [10]. The
investigators randomized1630 H. pylori-positive subjects to
receive either eradication treatment or placebo. After a follow
up of 7.5 years, the incidence of gastric cancer did not signif-
icantly differ between the two groups. However, subgroup
analysis of those subjects who had not had any signs of pre-
malignant lesions at baseline showed that H. pylori
eradication in this subgroup completely prevented gastric can-
cer whereas placebo treatment did not (p=0.02) [10].
A population-based study in Matsu, a Taiwanese island
with very high gastric cancer incidence, introduced an
H. pylori test-and-treat strategy. The incidence of gastric can-
cer was compared to an earlier cohort with known H. pylori
status but without eradication treatment forH. pylori-positives
[11•]. This comparison suggested that H. pylori eradication
led to a 25 % decline in gastric cancer incidence.
Several studies from Japan support the findings of these
population studies. A study in Japanese peptic ulcer patients
demonstrated that successful H. pylori eradication resulted in
a decline in cumulative 5-year gastric cancer incidence from
3.8 to 1.2 % [12]. Another Japanese study identified 1476
H. pylori-positive patients, of whom 853 chose to receive
eradication treatment and 624 did not. All patients were of-
fered follow up. Eventually, 404 patients in whom H. pylori
had been successfully eradicated and 304 patient who did not
receive eradication treatment were followed up for 3 years.
Gastric cancer occurred in 1.5 % in the eradicated group ver-
sus 4.3 % in the non-eradicated group (p 0.019) [13].
A Cochrane meta-analysis further addressed the impact of
H. pylori eradication on prevention of gastric neoplasia [14•].
It included 6 randomized controlled studies with 6497 sub-
jects, of whom 3294 received H. pylori eradication treatment
and 3203 placebo. H. pylori eradication was associated with
an RR of 0.66 (95 % CI 0.46–0.95) for development of gastric
cancer compared to placebo [14•]. The studies included in this
Fig. 1 Incidence of gastric cancer in age-specific rate (ASR) worldwide in 2012. Reprinted by permission from GLOBOCAN 2012 (IARC), http://
globocan.iarc.fr/, © IARC 2016, © WHO 2016
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analysis were all performed in Asian populations, studies in
other populations are till now lacking [14•].
Based on these data, the Japanese Society for Helicobacter
Research advocated H. pylori eradication for prevention of
gastric cancer. In 2013, the Japanese government decided to
subsidize population H. pylori test-and-treat strategies to pre-
vent gastric cancer. This has led to a massive increase in the
number of annual treatment prescriptions to more than a mil-
lion treatments per year [15].
While the use of H. pylori eradication for prevention of
gastric cancer is thus expanding, it remains a matter of debate
whether this is of sole benefit to subjects without premalignant
lesions or whether it also decreases the incidence of gastric
cancer in patients with premalignant lesions and those who
were treated for early gastric cancer. A further paper based on
the Shandong Intervention trial described the effects of
H. pylori eradication treatment in subjects with different
stages of precancerous lesions [16]. A total of 2172 subjects
were included, of whom 1285 had intestinal metaplasia or
dysplasia at baseline. H. pylori eradication treatment resulted
in a statistically significant reduction in incidence of gastric
cancer (HR 0.56, 95 % CI 0.34–0.91) and a non-significant
reduction in gastric cancer mortality (HR 0.63, 95 % CI 0.29–
1.37) in patients with intestinal metaplasia or dysplasia at
baseline. These findings suggested that H. pylori eradication
treatment is effective for prevention of cancer in subjects with
intestinal metaplasia and dysplasia [16]. Other studies, such as
the previously described mass eradication trial in Matsu, in
contrast demonstrated no risk regression in subjects with in-
testinal metaplasia or dysplasia [11•].
The effect of eradication of H. pylori in patients treated for
early gastric cancer and the risk of metachronous gastric can-
cer remains controversial. Three Japanese studies demonstrat-
ed a 58 to 100% significant reduction in metachronous gastric
cancer after H. pylori eradication during a follow-up period of
2 to 5 years [17–19]. In contrast, a retrospective multicenter
trial did not show a reduction in the incidence of
metachronous gastric cancer after a mean follow up of 3 years
[20•]. More recently two studies further analyzed the effect of
H. pylori eradication on metachronous gastric cancer. A
Korean study retrospectively analyzed subjects who had un-
dergone endoscopic resection for early gastric cancer [21•].
The authors compared patients without H. pylori infection
with those who had undergone successful eradication and pa-
tients with persistent H. pylori infection. The incidence of
metachronous gastric cancer was 10.9 per 1000 person-years
in the H. pylori-negative group, 14.7 in the eradicated group,
and 29.7 in the group with persistent H. pylori infection
(p<0.01).[21•]. Another Korean study with a median follow
up of 4.5 years yielded similar results [22]. These studies
suggest that H. pylori eradication after treatment for early
gastric cancer can result in a reduction in the incidence of
metachronous gastric cancer.
Population screening and eradication of H. pylori, the so-
called population test-and-treat strategy, may be a cost-
effective approach. A review by our group demonstrated that
this strategy may be cost-effective in countries with high as
well as low prevalence ofH. pylori. All studies included in the
review reported that screening for H. pylori to prevent gastric
cancer in the general population costs less than US$50,000 per
life year gained, a commonly used definition for cost-
effectiveness in literature [23•].
Such an approach however has a number of potential lim-
itations. These include the requirement for substantial popu-
lation participation, treatment failure due to limited compli-
ance and antimicrobial resistance, and reinfection. Although
H. pylori reinfection rates tend to be low (i.e., less than 2 %),
higher reinfection rates have been reported in countries such
as Bangladesh and India with a high prevalence of
Helicobacter in combination with poor sanitation and low
standards of living [24]. Therefore, vaccination would theo-
retically be a perfect intervention; however, the development
of a preventive and/or therapeutic vaccine has been disap-
pointing until now [25].
Screening and Surveillance of Premalignant Lesions
Since gastric cancer has specific precursor lesions, screening
for identification of patients with these lesions and their sur-
veillance may in theory also result in a lower incidence and
mortality of gastric cancer. Population screening is most rele-
vant for high incidence countries. It is in particular applied in
Japan and Korea. Screening can be performed by endoscopy
or serology. Endoscopic screening is based on thorough ex-
amination of the stomach lining either by endoscopic evalua-
tion alone, as is the practice in Japan, with use of scoring
systems [26•, 27]. Western clinicians generally prefer endo-
scopic examination in combination with random and targeted
biopsy sampling with the use of the OLGA orOLGIM scoring
systems as proposed in the MAPS guidelines [28, 29•, 30].
Serologic screening is in particular based on pepsinogen I,
II, and their ratio, sometimes combined with H. pylori serolo-
gy and measurement of fasting gastrin. Measurement of pep-
sinogen I and II offer a sensitivity of 69–70% and a specificity
of 88–97 % for the diagnosis of extensive chronic atrophic
gastritis (CAG).[31•, 32] Subjects with pathologic serology
are recommended to undergo endoscopy to assess the severity
and extent of the (pre)malignant lesions.
The impact of endoscopic and serologic screening has both
been studied in different populations. These studies firstly
suggested that endoscopic screening in high prevalence coun-
tries leads to a reduction in gastric cancer deaths. A gastric
cancer screening program in Niigata offered yearly screening
with endoscopy [33•]. This resulted among participants in a
57% reduction in gastric cancer deaths over a period of 5 years
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but the participation rate was only 25 % [33•]. A further case-
control study by the same group evaluated the impact of en-
doscopic screening in five Japanese cities [34]. Participation
in the screening program resulted in a 30 % reduction in gas-
tric cancer mortality over a period of 3 years, but only 10% of
the target population participated. Since screening programs
can only be effective on a population level if substantially
higher participation rates are achieved, large efforts would
be needed to make endoscopic screening a general success.
Serologic screening is potentially an elegant and more
widely applicable alternative for endoscopic screening.
Several studies based on a cohort of middle-aged Japanese
employees demonstrated that the combination of H. pylori
serology and serum pepsinogen levels can be applied as a
screening method to identify subjects at high risk for gastric
cancer [35, 36, 37•]. In total, 4655 employees were included
and followed for a mean 16 years. The subjects were divided
in four groups depending on H. pylori status and pepsinogen
levels. The first group was H. pylori-negative with normal
pepsinogen levels, the second group was H. pylori-positive
with normal pepsinogens, the third group was H. pylori-pos-
itive with low pepsinogens, and the final group wasH. pylori-
negative with low pepsinogens. In comparison withH. pylori-
negative subjects with normal pepsinogens, gastric cancer risk
rose stepwise in H. pylori-positive subjects with normal pep-
sinogens (HR 8.9, 95 % CI 2.7–54.7), in H. pylori-positive
subjects with low pepsinogens (HR 17.7, 95% CI 5.4–108.6),
and in H. pylori-negative subjects with low pepsinogens (HR
69.7, 95 % CI 13.6–502.9) [37•]. The latter group presumably
has the most advanced atrophy and as a result has spontane-
ously eradicated H. pylori. A recent study conducted in
Siberia confirmed these findings and demonstrated that the
use of the pepsinogen I/II ratio was a reliable marker to iden-
tify patients at risk of developing gastric cancer, which could
then be included in endoscopic surveillance [38]. There are
some concerns on the limited predictive value of pepsinogens,
and uncertainties on optimal cut-offs, but the negative predic-
tive value is high [39]. A limitation of these tests is that use of
a PPI may affect pepsinogens and gastrin levels.
A recent paper addressed the cost-effectiveness of gastric
cancer prevention using a mathematical microsimulation
model [40]. This model was based on the US population and
focused on prevention by means of an H. pylori test-and-treat
or detection and surveillance of premalignant lesions by
means of pepsinogen measurements or endoscopy. These
strategies reduced the lifetime risk for gastric cancer with re-
spectively 0.2, 26, and 21%. None of the interventions proved
to be cost-effective except in subgroups at high risk.
Although endoscopic screening is cost-effective in low in-
cidence countries, surveillance of patients with precancerous
lesions may be. Surveillance would aim for early detection of
cancer allowing for curative therapy and reduction of mortal-
ity. Recently, a Markov model-based study demonstrated that
endoscopic screening of patients with extensive atrophic gas-
tritis or intestinal metaplasia is cost-effective [41]. The 2012
MAPS guidelines propose endoscopic surveillance every
3 years for patients with extensive intestinal metaplasia
[29•]. A Korean study based on 2845 subjects demonstrated
that surveillance with a 3-year interval allowed early diagnosis
of gastric cancer with similar benefits as annual or biennial
surveillance. Prolonging the surveillance interval to 4 years or
more however increased the risk of more advanced stage gas-
tric cancer is [42•]. Studies on surveillance of patients with
precancerous lesions in low incidence countries are rare but
also suggest risk reduction and improved survival of gastric
cancer [43].
Healthy Lifestyle
Lifestyle factors such as diet, smoking, and use of alcohol
significantly influence the risk of gastric cancer and are thus
potential targets for disease prevention. This has been ad-
dressed in the prospective EPIC cohort study that aims to
investigate the relationship between chronic diseases and life-
style, diet, and environmental factors. The study included over
500,000 subjects in 23 centers across 10 European countries
[44]. It showed that a healthy diet, no smoking or alcohol use,
a normal BMI, and regular physical activity resulted in a 10%
reduction of gastric cancer risk.[45•]
Diet
Several dietary factors modulate the risk for gastric cancer.
This firstly pertains to a high intake of salt. A prospective
study of 2476 subjects followed for a mean of 14 years dem-
onstrated a significant association between high salt intake
and gastric cancer with a hazard ratio of 2.87 (95 % CI
1.14–7.24) in H. pylori-positive subjects with atrophic gastri-
tis [46]. An earlier population-based study obtaining sodium
urine samples in populations of 24 countries demonstrated a
significant correlation between stomach cancer mortality and
the amount of sodium intake [47].
The EPIC study demonstrated an inverse correlation be-
tween the level of intake of fruit and vegetables and the risk
of developing diffuse gastric cancer. However, this association
seemed to be restricted to subjects who smoked [48•]. A fur-
ther paper showed no association between the variety in veg-
etable and fruit intake and the risk of gastric cancer in low
incidence countries [49•]. Similarly, no association was dem-
onstrated between gastric cancer risk and the so-called
Mediterranean diet [45•].
A further dietary factor that has been correlated to the risk
of gastric cancer is fiber intake. Dietary fibers may neutralize
potentially carcinogenic nitrites and thus reduce their
intragastric concentration [50]. A meta-analysis showed a
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significant inverse correlation between dietary fiber intake and
gastric cancer risk [51]. An increase of 10 g of dietary fiber per
day was associated with a 44 % decreased risk of gastric
cancer.
The role of vitamin intake in risk reduction of gastric can-
cer was studied in a recent meta-analysis. This provided evi-
dence that even a relatively low dose intake of vitamin A
(1.5 mg/day), C (100 mg/day), and E (10 mg/day) are associ-
ated with a significant decrease of gastric cancer risk, with a
relative risk of 0.71 for vitamin A (95 % CI 0.62–0.810), 0.74
for vitamin C (95 % CI 0.69–0.79), and 0.76 for vitamin E
(95 % CI 0.67–0.85) [52].
The Shandong intervention trial also studied dietary inter-
ventions to reduce gastric cancer incidence. Next to H. pylori
eradication subjects were supplemented with garlic extract
and garlic oil or with a mixture of vitamin C, E, and selenium.
Vitamin treatment showed a trend toward a reduction of gas-
tric cancer mortality which was not statistically significant
(HR 0.55, 95 % CI 0.29–1.03) and garlic treatment did not
affect gastric cancer mortality [9•]. This contrasted with a
recent meta-analysis which concluded that any level of garlic
intake was associated with a reduced risk of gastric cancer
(OR 0.77; 95 % CI 0.6–1.0) [53]. High garlic intake reduced
the risk further (OR 0.49, 95 % CI 0.38–0.62). A large cohort
study on the effects of low intake of folate, methionine, vita-
min B6, and vitamin B12 demonstrated an increased risk of
esophageal squamous cell carcinoma, but no effect on gastric
cancer risk [54].
Green tea is known for its strong antioxidant activity and
can therefore enhance the overall chemopreventive effect of
intragastric antioxidants. In a systematic review of six cohort
studies on green tea intake and gastric cancer incidence, a
limited protective effect of green tea was observed in women
who drank at least five cups of tea per day.[55] A Cochrane
meta-analysis demonstrated conflicting results in the included
studies, concluding that there was moderate to strong evidence
that green tea did not reduce the risk of dying from gastric
cancer [56].
Smoking and Alcohol
Smoking is also an established risk factor for gastric cancer
[57]. The EPIC study demonstrated during a mean follow up
of 11.4 years that never smoking or quitting >10 years previ-
ously was associated with a decreased risk of developing gas-
tric cancer (HR 0.64, 95 % CI 0.54–0.75). This was the basis
for a further simulation model-based study considering sero-
logic screening, with either H. pylori testing or serum pepsin-
ogens, to reduce gastric cancer risk in smokers and non-
smokers. It was demonstrated that serum pepsinogen screen-
ing was not warranted for the general population because of an
incremental cost-effectiveness ratio (ICER) of more than
US$100,000 per QALY. However, in the subgroup of
smokers, the ICER was below 93,000 per QALY in all of
the proposed scenarios [40]. Furthermore, a strong association
was demonstrated between alcohol intake and gastric cancer
(HR 0.74, CI 053–0.97) [45•]. This association, however, was
only found in heavy consumers of alcohol [58]. Not only are
smoking and drinking an established risk factor for the devel-
opment of gastric cancer but both factors may also be associ-
ated with failure of H. pylori eradication [59].
Obesity
The EPIC study found no association between BMI and gas-
tric cancer risk [60]. Similar results were obtained in a range of
other studies, as well as in a meta-analysis that included 24
prospective studies [61].
Pharmacological Interventions
Several studies and two recent meta-analyses looked at the
impact of certain drugs, in particular statins and non-
steroidal antiinflammatory drugs on gastric cancer incidence
[62•, 63]. Most studies included in the meta-analyses were
population-based. The randomized trials that were included
had not been set up to identify a possible association between
statins and gastric cancer. However, both meta-analyses dem-
onstrated statin use was associated with a reduced risk of
gastric cancer. The risk reduction was modest, and the number
needed to treat to prevent one gastric cancer case would be
high.
Cox-2 is involved in H. pylori-associated gastric carcino-
genesis [64]. Some cohort studies reported that NSAIDs, such
as aspirin or celecoxib, intake reduced the incidence of gastric
cancer. A meta-analysis of 14 studies with 5000 cases and 30,
000 controls demonstrated a significant protective effect of
aspirin use on non-cardia gastric cancer (OR 0.62, 95 % CI
0.55–0.69) [65]. This observation was confirmed by a recent
Korean population-based study. This study based on the
Korean National Health Insurance claim database included
3907 cases using aspirin 100 mg daily and 7808 matched
controls [66•]. Regular aspirin was associated with a non-
significant reduced risk of gastric cancer (HR 0.71, 95 % CI
0.47–1.08; p=0.1); subjects using aspirin for 3 years or more
had a significantly lower gastric cancer risk (HR 0.4; 95 % CI
0.16–0.98; p=0.04). Every year of aspirin use resulted in a
further reduction of the gastric cancer risk [66•]
A randomized placebo-controlled trial aimed to study the
role of the selective Cox-2 inhibitor, celecoxib, with or with-
out H. pylori eradication in a high risk gastric cancer popula-
tion [67•]. Celecoxib use was associated with a significant
52 % regression in premalignant gastric lesions compared to
placebo, a percentage comparable to the effect of H. pylori
eradication (54 %). However, the combination of initial
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H. pylori eradication followed by celecoxib did not result in
additional beneficial effects compared toH. pylori eradication
alone.
Conclusions
Gastric cancer remains a prevalent disease with a very poor
prognosis. Most patients with gastric cancer die despite ag-
gressive multimodality treatment. This can generally be ex-
plained by the fact that most gastric cancers are diagnosed in a
late stage. Therefore, measures are warranted focusing on pre-
vention and early diagnosis.
H. pylori gastritis is the predominant risk factor for devel-
oping gastric cancer and most can be gained from H. pylori
eradication. Eradication could either be population-based or
focusing on subjects at highest risk. In high-incidence coun-
tries, population-based eradication seems a worthwhile inter-
vention. However, the success of such intervention depends
entirely on participation rates and the possible consequences
of widespreadH. pylori eradication are currently incompletely
understood. A more targeted approach can consist of treating
only high-risk groups or, for example, subjects over a certain
age. Recent data suggest thatH. pylori eradication at any stage
of gastritis has a beneficial effect on the risk of developing
gastric cancer and results in a decrease in gastric cancer
incidence.
Other measures to reduce gastric cancer incidence andmor-
tality aim to identify patients with premalignant lesions either
by endoscopic or serologic screening. Endoscopic screening
has the highest accuracy for assessment of the gastric mucosa
but is on a population level only feasible in high-risk popula-
tions given the costs and the number needed to screen.
Serologic screening is an elegant alternative. Surveillance of
subjects with premalignant lesions is currently advocated in
high- as well as low-incidence countries, and available data
seem to support this practice.
Further interventions to lower gastric cancer incidence aim
at promotion of a healthy lifestyle with adequate fiber, garlic
and vitamin intake, modest alcohol use, and no smoking.
Pharmacological interventions are of interest, but the results
so far are disappointing. Statin use leads to a modest risk
reduction and consequently a high number of subjects need
to be treated long-term to prevent a single case of gastric
cancer. Cox-2 inhibitors do not lead to an additional beneficial
effect after H. pylori eradication.
In the coming decade, the effect of large-scale H. pylori
eradication will be further elucidated, since the Japanese gov-
ernment started subsidization of population H. pylori eradica-
tion. This may also provide further answers on the positive
and negative effects of H. pylori eradication. With respect to
serologic screening, more data are needed on optimal selec-
tion of cut-offs and screening intervals in different
populations. With these data, maximal impact of serologic
screening can be clarified. Endoscopic surveillance is already
in place in several countries and the effects of this intervention
will become clear before long. The coming years will likely
also bring more data on lifestyle and pharmacological inter-
ventions. Together, these measures will bring options to re-
duce the very high worldwide incidence and mortality of gas-
tric cancer.
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